WO2001068851A3 - Polypeptides and nucleic acids encoding same - Google Patents

Polypeptides and nucleic acids encoding same Download PDF

Info

Publication number
WO2001068851A3
WO2001068851A3 PCT/US2001/007735 US0107735W WO0168851A3 WO 2001068851 A3 WO2001068851 A3 WO 2001068851A3 US 0107735 W US0107735 W US 0107735W WO 0168851 A3 WO0168851 A3 WO 0168851A3
Authority
WO
WIPO (PCT)
Prior art keywords
novx
polypeptides
nucleic acids
acids encoding
encoding same
Prior art date
Application number
PCT/US2001/007735
Other languages
French (fr)
Other versions
WO2001068851A2 (en
Inventor
Muralidhara Padigaru
Corine A M Vernet
Elma Fernandes
Richard A Shimkets
Steven K Spaderna
Kumud Majumder
Li Li
Original Assignee
Curagen Corp
Muralidhara Padigaru
Corine A M Vernet
Elma Fernandes
Richard A Shimkets
Steven K Spaderna
Kumud Majumder
Li Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Muralidhara Padigaru, Corine A M Vernet, Elma Fernandes, Richard A Shimkets, Steven K Spaderna, Kumud Majumder, Li Li filed Critical Curagen Corp
Priority to CA002402248A priority Critical patent/CA2402248A1/en
Priority to EP01916558A priority patent/EP1263955A2/en
Priority to AU2001243569A priority patent/AU2001243569A1/en
Priority to JP2001567335A priority patent/JP2003526369A/en
Publication of WO2001068851A2 publication Critical patent/WO2001068851A2/en
Publication of WO2001068851A3 publication Critical patent/WO2001068851A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
PCT/US2001/007735 2000-03-10 2001-03-12 Polypeptides and nucleic acids encoding same WO2001068851A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002402248A CA2402248A1 (en) 2000-03-10 2001-03-12 Polypeptides and nucleic acids encoding same
EP01916558A EP1263955A2 (en) 2000-03-10 2001-03-12 Polypeptides and nucleic acids encoding same
AU2001243569A AU2001243569A1 (en) 2000-03-10 2001-03-12 Novel polypeptides and nucleic acids encoding same
JP2001567335A JP2003526369A (en) 2000-03-10 2001-03-12 Novel polynucleotides and nucleic acids encoding the same

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US18831600P 2000-03-10 2000-03-10
US18827700P 2000-03-10 2000-03-10
US60/188,277 2000-03-10
US60/188,316 2000-03-10
US18913900P 2000-03-14 2000-03-14
US18914000P 2000-03-14 2000-03-14
US60/189,140 2000-03-14
US60/189,139 2000-03-14
US19040100P 2000-03-17 2000-03-17
US19023100P 2000-03-17 2000-03-17
US60/190,231 2000-03-17
US60/190,401 2000-03-17

Publications (2)

Publication Number Publication Date
WO2001068851A2 WO2001068851A2 (en) 2001-09-20
WO2001068851A3 true WO2001068851A3 (en) 2002-06-20

Family

ID=27558789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007735 WO2001068851A2 (en) 2000-03-10 2001-03-12 Polypeptides and nucleic acids encoding same

Country Status (5)

Country Link
EP (1) EP1263955A2 (en)
JP (1) JP2003526369A (en)
AU (1) AU2001243569A1 (en)
CA (1) CA2402248A1 (en)
WO (1) WO2001068851A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079270A2 (en) 2000-04-14 2001-10-25 The Queen's University Of Belfast Migraine and vasodilation treatment
AU2002213150A1 (en) * 2000-10-10 2002-04-22 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
EP1574576A1 (en) * 2000-10-10 2005-09-14 Lexicon Genetics Incorporated Novel human ion channel protein and polynucleotides encoding the same
WO2003055909A1 (en) * 2002-01-02 2003-07-10 Bayer Healthcare Ag Regulation of human fatty acid binding protein
DE102005026710A1 (en) * 2005-06-09 2006-12-14 Basf Ag Method for testing substances or substance mixtures, their use and corresponding analysis kits

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 4 February 2000 (2000-02-04), SMITH, D.R.: "Homo sapiens chromosome 10 clone RP11-111N20, complete sequence.", XP002186551, Database accession no. AC022387 *

Also Published As

Publication number Publication date
AU2001243569A1 (en) 2001-09-24
JP2003526369A (en) 2003-09-09
EP1263955A2 (en) 2002-12-11
CA2402248A1 (en) 2001-09-20
WO2001068851A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
WO2001092523A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001007595A3 (en) Novel fibroblast growth factor and nucleic acids encoding same
WO2001036645A3 (en) Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
WO2004048521A3 (en) Composition and method for treating lupus nephritis
WO2001049729A3 (en) Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
WO2001090366A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2002066647A3 (en) Type 2 ctokine receptor and nucleic acids encoding same
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
WO2001074856A3 (en) Wnt-7b-like polypeptides and nucleic acids encoding same
WO2001070978A3 (en) Polypeptides and nucleic acids encoding same
WO2001062928A3 (en) Polypeptides and nucleic acids encoding same
WO2002002625A3 (en) Novel fibroblast growth factors and nucleic acids encoding same
WO2001061009A3 (en) Polypeptides and nucleic acids encoding same
WO2001036638A8 (en) Polypeptides and nucleic acids encoding same
WO2001044473A3 (en) Polypeptides and nucleic acids encoding same
WO2003025147A3 (en) Novel polynucleotides and proteins encoded thereby
WO2001068851A3 (en) Polypeptides and nucleic acids encoding same
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
WO2001032874A3 (en) Polypeptides and nucleic acids encoding same
WO2000070046A3 (en) Secreted polypeptides and corresponding polynucleotides
WO2001023561A3 (en) Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats
WO2003040345A3 (en) Type 2 cytokine receptor and nucleic acids encoding same
WO2001023572A3 (en) Polynucleotides and polypeptides encoded thereby
WO2001061008A3 (en) Polypeptides and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 567335

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2402248

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001243569

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001916558

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001916558

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001916558

Country of ref document: EP